A Study to Evaluate ABP 206 Compared With OPDIVO ® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Condition:   Melanoma Interventions:   Drug: ABP 206;   Drug: Nivolumab Sponsor:   Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials